Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT05217485 Not yet recruiting - Atrial Fibrillation Clinical Trials

Continuous Ambulatory Cardiac Monitoring for Recurrent Atrial Fibrillation After Sepsis

CAMS-AF
Start date: March 2022
Phase: N/A
Study type: Interventional

To detect atrial fibrillation after infection.

NCT ID: NCT05212935 Not yet recruiting - Vaccination Clinical Trials

A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy

STORM
Start date: May 2022
Phase:
Study type: Observational

A two-phases study will be carried out with the following aims 1. st phase (2018-2020) - To investigate the vaccination coverage for Rotavirus vaccine (RV) in Campania Region together with other pediatric vaccinations scheduled in the first 12 months of life: hexavalent, pneumococcal conjugate (PCV), meningococcal B (MenB) - To collect data on appropriate timing of the 3 doses of human bovine pentavalent reassortant vaccine (RV5) administration - To evaluate the frequency of a co-administration of RV5 with other vaccines scheduled in the first 12 months of life (hexavalent/PCV+RV5, MenB+RV5 vs RV5 alone) and assess the variability in co-administration rates according to RV5 dose 2. nd phase (2020-2022) - To investigate the effect of Coronavirus-Disease-19 (COVID-19) pandemic on vaccination coverage in the first year of life, focusing on RV vaccination - To investigate the effect of COVID-19 pandemic on timing of vaccine administration in the first year of life, focusing on those vaccines without catch-up vaccination schedule (i.e. RV) Hypothesis are the following: - Vaccination coverage and timing of vaccines scheduled in the first year of life are not fully aligned with what is established by the Italian National Prevention Plan 2017-2019 - Co-administration of RV5 and MenB in comparison with other coadministration e.g. hexavalent/PCV is lower - Co-administration of RV5 and MenB allows to ensure appropriate timing of RV vaccination schedule - COVID-19 pandemic may have affected the overall vaccination coverage as well as the timing of selected vaccination scheduled in the first year of life, with a more relevant impact on vaccines for whom a catch-up vaccination schedule is not feasible, such as RV immunization.

NCT ID: NCT05208333 Not yet recruiting - Toxocara Infection Clinical Trials

The Effectiveness of Albendazole Treatment Among Infected Toxocara Children

Start date: May 2022
Phase: N/A
Study type: Interventional

This study consists 2 phases. The first phase will conduct a cross-sectional study to determine the infection rate of Toxocariasis larvae, describe the clinical and paraclinical characteristics, identify risk factors related to Toxocariasis larva infection. The second phase will conduct an interventional study to evaluate the effectiveness and factors related to the Albendazole treatment on pupils infected with Toxocariasis larvae in Ho Chi Minh City.

NCT ID: NCT05204368 Not yet recruiting - Clinical trials for Complicated Urinary Tract Infection Including Acute Pyelonephritis

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Start date: March 30, 2023
Phase: Phase 3
Study type: Interventional

This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.

NCT ID: NCT05185778 Not yet recruiting - Clinical trials for Protozoan Infections

Parasitism & COVID19 Vaccines: New Challenge.

Start date: April 1, 2022
Phase:
Study type: Observational

- Parasitic infection is a serious public health problem throughout the world particularly in developing countries including Egypt. The individuals infected with helminths are responding to the parasite infections by a specific Th2 type innate and adaptive immune responses. The Coronavirus Disease 2019 pandemic has affected over 169 million people and caused the death of millions worldwide. COVID vaccines with up to 95% of efficacy and effectiveness have been developed and approved by the Food and Drug Administration (FDA), USA. Moreover, it's reported that vaccination against COVID may lead to Cytokine Storm Syndrome in some vaccinated people with release of large amounts of cytokines as (IFNγ, IL-12, TNFα).

NCT ID: NCT05172063 Not yet recruiting - Clinical trials for SARS-CoV-2 Infection

Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness

Start date: January 2022
Phase:
Study type: Observational

The main goal of this study is to characterize the adaptive immune responses to SARS-CoV-2 infection in a cohort of children with cancer and impaired immune responsiveness and prolonged viral shedding of SARS-CoV-2, and to identify SARS-CoV-2 variants that might arise during poorly controlled virus replication

NCT ID: NCT05161299 Not yet recruiting - Surgery Clinical Trials

CovidSurg-3: Outcomes of Surgery in COVID-19 Infection

CovidSurg-3
Start date: December 13, 2021
Phase:
Study type: Observational

COVID-19 has significant detrimental impacts on surgical systems and patient outcomes. CovidSurg has provided the best available evidence to guide delivery of safe surgery during the pandemic. However, CovidSurg data were collected in 2020 when the wildtype SARS-CoV-2 virus was dominant, and therefore there is a need to for renewed rapid data to guide global practice during Omicron COVID-19 waves. CovidSurg-3 is an extension to CovidSurg and was initiated in response to the emergence of the Omicron variant. CovidSurg-3 has two separate components: - Patient-level component: Collection of outcome data for patients with peri-operative SARS-CoV-2. - Hospital-level component: Collection of aggregated case-mix data. Hospitals in countries with low community SARS-CoV-2 infection rates can contribute towards this component.

NCT ID: NCT05142813 Not yet recruiting - Sepsis Clinical Trials

A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children

Start date: May 2022
Phase:
Study type: Observational

A case-control cohort study to develop and validate the performance of a whole blood gene expression test to distinguish sepsis infection from uninfected systemic inflammatory response syndrome cases in symptomatic adults and children without comorbidities.

NCT ID: NCT05141188 Not yet recruiting - Clinical trials for Urinary Tract Infections

Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections

Start date: December 1, 2021
Phase:
Study type: Observational

Urinary tract infection is among the most common nosocomial and community acquired infections. The Information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy .Resistance to antibiotic treatment in patients with urinary tract infections (UTIs) is a representative example of the increasing problem of antimicrobial resistance. Extended-spectrum β-lactamases (ESBLs) has emerged as an important mechanism of resistance in Gram-negative bacteria.

NCT ID: NCT05139628 Not yet recruiting - Clinical trials for Catheter-Related Infections

Peripheral Venous Catheter Related Blood Stream Infections

Start date: July 1, 2023
Phase:
Study type: Observational

The aim of this work is to: 1. Study the impact of PIVC skin colonization on catheter tip colonization and the development of CRBSI 2. isolate and identify the organisms causing peripheral venous catheter related blood stream infections in pediatric oncology patients. 3. perform antimicrobial sensitivity testing of isolated organisms. 4. identify the associated risk factors that lead to CRBSIs in such group of patients.